Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Amgen
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01740297
First received: November 14, 2012
Last updated: February 23, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2017
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)